News Archives - Page 2 of 16

Emyria starts program with neuroscience drug discovery CRO

by Eric | Sep 22, 2022

Emyria starts program with neuroscience drug discovery CRO By Jim Cornall · Sept 22, 2022 · Labiotech.eu Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization...

Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More

by Eric | Sep 22, 2022

Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more...

Emyria teams with CRO PsychoGenics for MDMA-like drug development

by Eric | Sep 21, 2022

Emyria teams with CRO PsychoGenics for MDMA-like drug development By Joseph Keenan · Sep 21, 2022 · Fierce Biotech Australian biotech Emyria and U.S.-based CRO PsychoGenics have agreed to a collaborate on preclinical trials of MDMA-inspired drug candidates. Along with...

Overcoming mental health’s drug development challenges with AI

by Eric | Aug 24, 2022

Overcoming mental health’s drug development challenges with AI By Kelly Bilodeau · Aug. 23, 2022 · PharmaVoice PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant...

PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO

by Eric | Aug 22, 2022

PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO Aug. 22, 2022 · Health Professional Radio Mark Varney, Ph.D., Chief Scientific Officer of PsychoGenics, an AI-enabled phenotypic drug discovery and preclinical contract research organization (CRO) discusses...

« Older Entries

Next Entries »

Emyria starts program with neuroscience drug discovery CRO

Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More

Emyria teams with CRO PsychoGenics for MDMA-like drug development

Overcoming mental health’s drug development challenges with AI

PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO

Recent Comments

CONTACT